Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Nash

Kansas City, MO Medical Doctor

NPI 1942259692 CMS profile 179148

6400 Prospect Ave, Suite 228, Kansas City, MO 64132

Open in the dashboard

General payments

$417,505

338 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Steven Nash of Kansas City, MO is reported in the CMS Open Payments database as having received $417,505 across 338 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $126,649 103
2024 General $100,453 61
2023 General $37,411 21
2022 General $42,912 31
2021 General $31,515 25
2020 General $53,765 43
2019 General $24,801 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Nash
  • Missouri median
  • Middle half of Missouri
  • National median

In program year 2025, general payments to Steven Nash were reported at $126,649. Among 20,470 Missouri profiles paid that year, the median was $164 and the middle half received between $50 and $619.

Show as a table
Year Steven Nash Missouri median Middle half National median
2019 $24,801 $176 $52–$688 $163
2020 $53,765 $117 $36–$411 $114
2021 $31,515 $136 $37–$511 $132
2022 $42,912 $147 $42–$555 $149
2023 $37,411 $158 $46–$594 $160
2024 $100,453 $159 $47–$595 $164
2025 $126,649 $164 $50–$619 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Uromedica, Incorporated $403,633 271 payments
  2. Astellas Pharma US Inc $8,992 31 payments
  3. AbbVie, Inc. $4,117 7 payments
  4. Arthrex, Inc. $241 4 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $104 1 payment
  6. Janssen Biotech, Inc. $75 5 payments
  7. Blue Earth Diagnostics Limited $42 2 payments
  8. Endo Pharmaceuticals Inc. $42 2 payments
  9. C. R. Bard, Inc. & Subsidiaries $38 2 payments
  10. Ferring Pharmaceuticals Inc. $33 2 payments
  11. Other $188 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $219,000 81 payments
  2. Honoraria $110,000 29 payments
  3. Travel and Lodging $71,396 104 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,523 8 payments
  5. Food and Beverage $4,523 114 payments
  6. Education $63 2 payments
Products named General payments · program years 2019–2025
  1. ProACT Urological Implant $388,023 267 payments
  2. MYRBETRIQ $7,530 29 payments
  3. ACT $5,247 2 payments
  4. LUPRON DEPOT Endocrinology $2,943 4 payments
  5. LUPRON DEPOT Endocrinology $1,174 3 payments
  6. ProACT R6j17 $363 1 payment
  7. Xofigo $104 1 payment
  8. ERLEADA $75 5 payments
  9. GENTLECATH $51 3 payments
  10. Axumin $42 2 payments
  11. Other $206 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

338 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record